未经证实:腹部偏头痛(AM)是儿童非常常见的功能性胃肠病。这项研究报告了儿童AM的临床特征和对预防性治疗的反应。
UNASSIGNED:这项回顾性研究于2010年1月至2019年12月在阿曼苏丹国皇家医院进行。这项研究包括年龄≤13岁的儿童,根据罗马IV的功能诊断标准诊断为AM。临床,人口统计学,并收集治疗数据。
未经授权:确认了74名儿童,其中43人符合纳入本研究的条件.症状发作的中位年龄为7岁(范围,2-12年)。最常见的症状是头痛(81.4%),恶心(79.1%),和呕吐(72.1%)。在整个队列中,46.5%,23.3%,6.9%的人接受了核黄素,比佐替芬,和普萘洛尔单药治疗,分别。还使用了联合治疗;16.3%的儿童接受了吡唑替芬和普萘洛尔,4.7%接受核黄素和比佐替芬,2.3%接受核黄素和普萘洛尔治疗。普萘洛尔单药治疗的患者显示100%的临床改善,核黄素或吡唑替芬单药治疗的患者显示90%的临床改善。对吡唑替芬和普萘洛尔联合治疗的反应为71.4%,核黄素和比佐替芬的含量为100%。此外,治疗反应与呕吐的存在显著相关(p=0.039).
UNASSIGNED:我们发现了对各种方式和核黄素联合治疗的良好反应,比佐替芬,和普萘洛尔用于AM儿童。此外,呕吐的存在可以预测治疗反应。
UNASSIGNED: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children.
UNASSIGNED: This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected.
UNASSIGNED: Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2-12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039).
UNASSIGNED: We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.